论文部分内容阅读
利用抗人活化血小板α－颗粒膜蛋白（α－GranuleMembraneProtein，GMP－140）单抗SZ－51，经放免法评估22例急性脑血栓患者体内血小板的活化程度。结果血浆内GMP－140的含量在脑血栓急性期显著增高（P＜0．01），缓解期恢复正常，血小板表面GMP－140分子数未见显著改变。提示血浆内GMP－140的浓度可作为脑血栓急性期体外诊断新的参考指标。当兔颈动脉植入人血栓并用~125I－SZ－51作为示踪剂，4小时后离体血栓与血液的放射活性比值（Thrombus／Blood，T／B）高达6．8：1，而用~125I-IgG时T／B值仅为1.4:1，提示单抗SZ-51在体内能与血栓结合，为脑血栓的新的体内定位诊断方法提供了一定的理论依据。
The platelet activation in 22 patients with acute cerebral thrombosis was assessed by radioimmunoassay using monoclonal antibody SZ-51 against human activated platelet α-Granule Membrane Protein (GMP-140). Results The level of GMP-140 in plasma was significantly increased in the acute phase of cerebral thrombosis (P <0.01), and returned to normal in the remission stage. There was no significant change in the number of GMP-140 on the platelet surface. It is suggested that the concentration of GMP-140 in plasma can be used as a new reference index for the in vitro diagnosis of acute cerebral thrombosis. When the rabbit carotid artery was implanted with human thrombus and labeled with 125I-SZ-51 as a tracer, the ratio of thrombus to blood radioactivity (Thrombus / Blood, T / B) was as high as 6.8: 1 after 4 hours, ~ 125I-IgG T / B value of only 1.4: 1, suggesting that the monoclonal antibody SZ-51 in the body can be combined with thrombosis for the new diagnostic method of cerebral thrombosis in vivo provides a theoretical basis.